Hormonal deprivation therapy improves the survival of PCa patients, however, androgen receptor mutations often accompany tumour progression up to the point when cancer progresses to an androgen-independent state known as castration-resistant prostate cancer (CRPC), affecting nearly 20–30% of PCa patients. Here, AR is linked to neoplasm.